Clinical Trial

Chiauranib in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated March 18, 2026 (before its estimated May 31, 2026 completion). Its status may not reflect the trial's current state.
Summary
Chiauranib , which simultaneously targets against VEGFR/Aurora B/CSF-1R, several key kinases involved in tumor angiogenesis, tumor cell mitosis, and chronic inflammatory microenvironment.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-07-02; most recent amendment 2026-03-16.
Status change: Recruiting → Active, Not Recruiting 2026-03-16
Status change: Not Yet Recruiting → Recruiting 2025-03-28
Trial Details
NCT Number NCT06492915
Lead Sponsor Chipscreen Biosciences, Ltd.
Conditions Pancreatic Ductal Adenocarcinoma
Enrollment 42 participants
Start Date 2024-08-13
Primary Completion 2026-05-31 (estimated)
Study Completion 2026-10-31 (estimated)
Updated on ClinicalTrials.gov 2026-03-18